CALL FOR APPLICATIONS:
One Week Left to Apply for
Investor Summit
Applications for the LifeSciences BC 2019
Investor Summit presented Lumira Ventures & supported by adMare BioInnovations, will close next
Thursday, September 12.
We would like to invite
all life sciences companies to apply now.
Companies that are selected to present will receive complimentary tickets to attend the event that will be happening on Wednesday, November 6 at the
|
"
Accelerating Results in Clinical Trials Through Unified Technology Solutions"
|
LOCATION:
Terminal City Club, 837 West Hastings Street, Vancouver
|
|
LifeSciences BC Annual General Meeting 2019
|
DATE:
October 3
TIME:
8:00 AM
-
9:30 AM
LOCATION: Royal Bank Tower, 36th floor, 1055 West Georgia Street, Vancouver
AGENDA
8:00am: Continental Breakfast served
8:30am: Welcome remarks
8:35am: Annual General Meeting begins
9:30am: Annual General Meeting concludes
|
|
|
DATE:
October 7,2019
TIME:
8:00 AM
-
5:30 PM
LOCATION: Royal Bank Tower, 36th floor, 1055 West Georgia Street, Vancouver
AGENDA
Swedish Trade and Invest Council and the Embassy of Sweden are arranging a free digital health seminar in collaboration with the Ministry of Health in BC, Global Affairs Canada, RBC and LifeSciences BC to share challenges and opportunities but also showcase innovative Swedish and British Columbian digital health technologies.
|
|
Showcasing MedTech Innovations in Healthcare
|
DATE:
October 9,2019
TIME:
6.00PM - 8.00PM
LOCATION: McCarthy Tetrault LLP, 2400 - 745 Thurlow Street, Vancouver
Presenting
Companies:
- BioLytical Laboratories Inc.
Presentations
7:15 - 8:15pm - Wine & Appetizer Reception and Networking Opportunity
Tickets: LSBC member $25 and LSBC non-member $50
|
|
DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials
|
VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2019 /PRNewswire/ -
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company anticipates that its current cash position, which includes the $6.7 million in net proceeds from the underwritten offering completed August 16, 2019, will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 clinical trials for its lead compound, VAL-083, which the Company believes will occur by the fourth quarter of calendar year 2020.
|
|
Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases
VANCOUVER, British Columbia, Aug. 22, 2019 /PRNewswire/ - Chinook Therapeutics, Inc. today announced a $65 million Series A financing to discover and develop precision medicines for kidney diseases. Founding investor Versant Ventures led the round with participation by fellow founding investor Apple Tree Partners and new investor Samsara BioCapital. READ MORE
|
DelMar Pharmaceuticals Relocates Headquarters to San Diego, California
SAN DIEGO, Sept. 4, 2019 /PRNewswire/ -
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company has relocated its headquarters from Vancouver, British Columbia to San Diego, California.
READ MORE
|
Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE, Sept. 05, 2019 (GLOBE NEWSWIRE) - Neoleukin Therapeutics, Inc. ("Neoleukin") (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated
computational methods to design de novo
protein therapeutics, today announced it has granted equity awards that were approved by the Compensation Committee of its Board of Directors on August 31, 2019 as a material inducement to employment to four individuals hired by Neoleukin.
READ MORE
|
Health Canada's first challenges under Innovative Solutions Canada
|
I
n August 2019, Health Canada launched three challenges seeking private sector solutions:
1) Point of Care Diagnostics to combat Antimicrobial Resistance
2) Machine Learning to Improve Organ Donation Rates and Make Better Matches
3) Identification of Microbial Mixtures
To find out more about the Innovative Solutions Canada program and these three challenges, as well as how to compete in developing a solution, please click on the following link: Innovative Solutions Canada program
Questions or comments?
|
|
Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report
Sep 4, 2019 |by
Arlene Weintraub
|
In the 1980s, only 4% of new drugs approved by the FDA were cancer treatments. But since 2010, cancer drugs have claimed 27% of new approvals-a share that doubled over the previous decade-according to a new report from the Tufts Center for the Study of Drug Development.
|
A novel technology for genome-editing a broad range of mutations in live organisms
Scientists develop a new gene-editing tool that could help treat many disorders caused by gene mutations
August 23, 2019 |
Salk Institute |
Researchers have developed a new tool -- dubbed SATI -- to edit the mouse genome, enabling the team to target a broad range of mutations and cell types. The new genome-editing technology could be expanded for use in a broad range of gene mutation conditions such as Huntington's disease and the rare premature aging syndrome, progeria.
|
Left-handed DNA found - and it changes brain structure
September 5, 2019 | By James GallagherHealth and science correspondent, BBC News | Scientists have found the first genetic instructions hardwired into human DNA that are linked to being left-handed. The instructions also seem to be heavily involved in the structure and function of the brain - particularly the parts involved in language.
|
approximately 60,000 visitors a month?
~
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings comes with a
free repost on Biotalent's
The Petri Dish?
After your first five reposts, you will also receive 25% off all job
postings on
The Petri Dish!
|
|
|
|
